Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer
Alona Zer(Rambam Health Care Campus), Lori J. Bernstein(St. Michael's Hospital), Kelvin Chan(Occupational Cancer Research Centre), Andrew Hope(University of Toronto), Hui Gan(Austin Hospital), Ilan Weinreb(University Health Network), John Waldron(Princess Margaret Cancer Centre), Brian O’Sullivan(University of Toronto), Gregory R. Pond(Juravinski Hospital), Kattleya Tirona(University of Toronto), Eric X. Chen(Princess Margaret Cancer Centre), Andrew K. Chan(University of Toronto), David P. Goldstein(University Health Network), Lillian L. Siu(University Health Network), Albiruni R. Abdul Razak(Mount Sinai Hospital), John J. Kim(University Health Network)
Cited by 56
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Dose Escalation Methods in Phase I Cancer Clinical Trials
|JNCI Journal of the National Cancer Institute|2009|856
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
|Journal of Clinical Oncology|2013|830
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
|Journal of Clinical Oncology|2010|806